Safety and Tolerability of Lactobacillus reuteri DSM 17938 and Effects on Biomarkers in Healthy Adults: Results from a Randomized Masked Trial
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There are few carefully-designed studies investigating the safety of individual probiotics approved under Investigational New Drug policies. OBJECTIVES: The primary aim of this prospective, double-blind placebo-controlled trial was to investigate if daily treatment of adults with Lactobacillus reuteri DSM 17938 (LR) for 2 months is safe and well-tolerated. Our secondary aim was to determine if LR treatment has immune effects as determined by regulatory T cell percentages, expression of toll-like receptors (TLR)-2 and -4 on circulating peripheral blood mononuclear cells (PMBCs), cytokine expression by stimulated PBMC, and intestinal inflammation as measured by fecal calprotectin. METHODS: Forty healthy adults were randomized to a daily dose of 5 × 10(8) CFUs of LR (n = 30) or placebo (n = 10) for 2 months. Participants completed a daily diary card and had 7 clinic visits during treatment and observation. RESULTS: There were no severe adverse events (SAEs) and no significant differences in adverse events (AEs). There were no differences in PBMC subclasses, TLRs, or cytokine expression after treatment. The probiotic-treated group had a significantly higher fecal calprotectin level than the placebo group after 2 months of treatment: 50 µg/g (IQR 24-127 µg/g) vs. 17 µg/g (IQR 11-26 µg/g), p = 0.03, although values remained in the normal clinical range (0-162.9 µg/g). LR vials retained >10(8) CFUs viable organisms/ml. CONCLUSIONS: LR is safe and well tolerated in adults, without significant changes in immunologic markers. There was a small but significant increase in fecal calprotectin, perhaps indicating some element of immune recognition at the intestinal level. TRIAL REGISTRATION: Clinical Trials.gov NCT00922727.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
O’Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O’Sullivan, G. C., Kiely, B., Collins, J. K., Shanahan, F., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.050 · Cited by 1,448
Besselink, M. G., van Santvoort, H. C., Buskens, E., Boermeester, M. A., van Goor, H., Timmerman, H. M., Nieuwenhuijs, V. B., Bollen, T. L., van Ramshorst, B., Witteman, B. J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60207-x · Cited by 1,367
Lactobacillus Sepsis Associated With Probiotic Therapy
Land, M. H., Rouster-Stevens, K., Woods, C. R., Cannon, M. L., Cnota, J., & Shetty, A. K. (2005) · Pediatrics · doi:10.1542/peds.2004-2137 · Cited by 599 · cited 1×
“There are reports of infections directly linked to the ingestion of probiotic products [6–9], and one multicenter trial of a probiotic for the treatment of patients with severe pancreatitis documented an increase in mortality in the treated group [10].”
BackgroundPathogenic relevance of Lactobacillus: A retrospective review of over 200 cases
Cannon, J. P., Lee, T. A., Bolanos, J. T., & Danziger, L. H. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1253-y · Cited by 478 · cited 1×
“Lactobacillus species are generally not considered pathogenic; however, probiotics have been implicated in rare cases of endocarditis and bacteremia in immunocompromised patients [5].”
BackgroundKehl-Fie, T. E., Chitayat, S., Hood, M. I., Damo, S., Restrepo, N., Garcia, C., Munro, K. A., Chazin, W. J., & Skaar, E. P. (2011) · Cell Host & Microbe · doi:10.1016/j.chom.2011.07.004 · Cited by 419 · cited 1×
“Calprotectin secreted by neutrophils has a demonstrated antimicrobial effect, aiding in the killing of fungi and Staphylococci by sequestration of nutrient metals, such as zinc and manganese [24].”
BackgroundTwo cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome
Kunz, A. N., Noel, J. M., & Fairchok, M. P. (2004) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/00005176-200404000-00017 · Cited by 319 · cited 1×
“There are reports of infections directly linked to the ingestion of probiotic products [6–9], and one multicenter trial of a probiotic for the treatment of patients with severe pancreatitis documented an increase in mortality in the treated group [10].”
BackgroundHuman-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammation
Liu, Y., Fatheree, N. Y., Mangalat, N., & Rhoads, J. M. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00124.2010 · Cited by 207 · cited 1×
“We and others have shown that LR reduces inflammation in intestinal cells and tissues in vitro [12,13], that LR reduces inflammation in the intestine of lipopolysaccharide-fed newborn rat pups [14], and LR reduces the incidence and severity of experimental necrotizing enterocolitis via modulation of TLR4 and NF-kB sig…”
BackgroundSelf-citation
Cited by
Role of Lactobacillus reuteri in Human Health and Diseases
Mu, Q., Tavella, V. J., & Luo, X. M. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00757 · Cited by 744
Bajaj, J. S., Heuman, D. M., Hylemon, P. B., Sanyal, A. J., Puri, P., Sterling, R. K., Luketic, V., Stravitz, R. T., Siddiqui, M. S., Fuchs, M., et al. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12695 · Cited by 274
Mobini, R., Tremaroli, V., Ståhlman, M., Karlsson, F., Levin, M., Ljungberg, M., Sohlin, M., Bertéus Forslund, H., Perkins, R., Bäckhed, F., et al. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12861 · Cited by 263
Comprehensive approaches for assessing the safety of probiotic bacteria
Pradhan, D., Mallappa, R. H., & Grover, S. (2020) · Food Control · doi:10.1016/j.foodcont.2019.106872 · Cited by 179
Abbaspour, N. (2024) · Applied Food Research · doi:10.1016/j.afres.2024.100468 · Cited by 161
Can probiotics benefit children with autism spectrum disorders?
Navarro, F., Liu, Y., & Rhoads, J. M. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i46.10093 · Cited by 154
Kazemi, A., Soltani, S., Ghorabi, S., Keshtkar, A., Daneshzad, E., Nasri, F., & Mazloomi, S. M. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2019.04.004 · Cited by 131
Dore, M. P., Bibbò, S., Fresi, G., Bassotti, G., & Pes, G. M. (2019) · Nutrients · doi:10.3390/nu11122913 · Cited by 83
Mohr, A. E., Basile, A. J., Crawford, M. S., Sweazea, K. L., & Carpenter, K. C. (2020) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2019.08.018 · Cited by 37
Fatheree, N. Y. (2016) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v7.i1.160 · Cited by 24
Self-citation
Metadata
- Authors
- Mangalat, N., Liu, Y., Fatheree, N. Y., Ferris, M. J., Van Arsdall, M. R., Chen, Z., Rahbar, M. H., Gleason, W. A., Norori, J., Tran, D. Q., & Rhoads, J. M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-09-06
- Volume
- 7
- Issue
- 9
- Pages
- e43910
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2010951122
- Cited by
- 59
- References
- 7
- FWCI
- 6.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.